Shanghai Cancer Institute

undefined

TU Hong

professor

Email: tuhong@shsci.org

Tel:86-21-64437196

Research field:Systemic regulation of liver and pancreatic cancers

Biography

  • Hong Tu, professor of oncology at Stated Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao-Tong University School of Medicine, is a medically trained researcher with graduate training in molecular virology at Shanghai Medical University and University of Southern California, and postgraduate training in cell biology at INSERM U370, Necker/Pasture institute, France. Dr. Tu has worked as a principal investigator in Shanghai Cancer Institute since 2002. She was a research instructor in Penning Biomedical Research Institute, Louisiana State University, USA (2005-2011) and a lecturer in Shanghai Medical University (1990-1996).  Her research interests include 1. Etiology of hepatocellular carcinoma. 2. Systemic regulation of pancreatic by nervous, endocrine and immune systems. Being a principal investigator, Dr. Tu has completed several projects from National Natural Science of China projects, Chinese State Key Project Specialized for Infectious Diseases, the National Key R&D Program of China and Shanghai Municipal Science and Technology Commission. She has published more than 120 papers in peer-reviewed journals, and has been granted 4 patents related to the prediction and early diagnosis of liver cancer.  Her research achievements were awarded several prizes including the second prize of National Natural Sciences Award, the first prize of scientific and technological progress from the Ministry of Education, etc. She is the editorial board of Hepatoma Research, Tumor and China Oncology. She serves as the referee of several national and international journals.

Selected Publications of the recent 5 years:

  1. Cong H, Gao J, Wang Q, Du M, Li H, Li Q, Li J, Liang Y, Zhao D, Yang H, Gan Y#, Tu H#. Increased Expression of Mitochondrial UQCRC1 in Pancreatic Cancer Impairs Antitumor Immunity of Natural Killer Cells via Elevating Extracellular ATP. 2022, Front Oncol, 12:872017.

  2. 117. Liang Y*, Li H*, Gan Y#, Tu H#. Shedding Light on the Role of Neurotransmitters in the Microenvironment of Pancreatic Cancer. Front Cell Dev Biol, 2021, 9:688953.

  3. .Li J*, Zhang W*, Gao J, Du M, Li H, Li M, Cong H, Fang Y, Liang Y, Zhao D, Xiang G, Ma X, Yao M, Tu H#, Yu Gan#. E3 Ubiquitin Ligase UBR5 Promotes the Metastasis of Pancreatic Cancer via Destabilizing F-Actin Capping Protein CAPZA1. Front Oncol. 2021,11:634167.

  4. Ding HG, Tu H, Qu C, et al. Guideline for stratified screening and surveillance in patients with high risk of primary liver cancer (2020) . Hepatoma Research, 2021, 7:17-41

  5. Yang C, Yuan H, Gu J, Xu D, Wang M, Qiao J, Yang X, Zhang J, Yao M, Gu J, Tu H#, Gan Y#. ABCA8-mediated efflux of taurocholic acid contributes to gemcitabine insensitivity in human pancreatic cancer via the S1PR2-ERK pathway. Cell Death Discovery. 2021,7(1):6.

  6. Li M, Du M, Cong H, Gu Y, Fang Y, Li J, Gan Y, Tu H#, Gu J#, Xia Q#. Characterization of hepatitis B virus DNA integration patterns in intrahepatic cholangiocarcinoma. Hepatol Res. 2021,51(1):102-115

  7. Li M, Shen Y, Chen Y, Gao H, Zhou J, Wang Q, Fan C, Zhang W, Li J, Cong H, Gu J, Gan Y, Tu H. Characterization of hepatitis B virus infection and viral DNA integration in non-Hodgkin lymphoma. Int J Cancer, 2020, 147(8):2199-2209.

  8. Xu D, Yuan H, Meng Z, Yang C, Li Z, Li M, Zhang Z, Gan Y#, Tu H#. Cadherin 13 Inhibits Pancreatic Cancer Progression and Epithelial-mesenchymal Transition by Wnt/β-Catenin Signaling. J Cancer, 2020, 11(8):2101-2112

  9. Wang Q, Li M, Gan Y, Jiang S, Qiao J, Zhang W, Fan Y, Shen Y, Song Y, Meng Z, Yao M, Gu J, Zhang Z, Tu H. Mitochondrial Protein UQCRC1 is Oncogenic and a Potential Therapeutic Target for Pancreatic Cancer. Theranostics, 2020, 10(5):2141-2157

  10. Meng Z*, Liu T*, Song Y, Wang Q, Xu D, Jiang J, Li M, Qiao J, Lu X, Gu J, Tu H#, Gan Y# Exposure to an Enriched Environment Promotes the Terminal Maturation and Proliferation of Natural Killer cells in Mice. Brain Behav Immun, 2019, 77:150–160

  11. Jiang J*, Fan Y*, Zhang W, Shen Y, Liu T, Yao M, Gu J, Tu H#, Gan Y#. Adiponectin suppresses human pancreatic cancer growth through attenuating the β-catenin signaling pathway. Int J Biol Sci, 2019, 15(2):253-264

  12. Fan C, Li M, Gan Y, Chen T, Sun Y, Lu J, Wang J, Jin Y, Lu J, Qian G, Gu J, Chen J, Tu H. A simple AGED score for risk classification of primary liver cancer: development and validation with long-term prospective HBsAg-positive cohorts in Qidong, China. Gut, 2019 68(5):948-949

  13. Li M, Gan Y, Fan C, Yuan H, Zhang X, Shen Y, Wang Q, Meng Z, Xu D, Tu H. Hepatitis B virus and risk of non-Hodgkin lymphoma: An updated meta-analysis of 58 studies.

  14. J Viral Hepat. 2018, 25(8): 894-903

  15. Song Y*, Gan Y*#, Wang Q, Meng Z, Li G, Shen Y, Wu Y, Li P, Yao M, Gu J, Tu H#. Enriching the Housing Environment for Mice Enhances Their NK Cell Antitumor Immunity via Sympathetic Nerve-Dependent Regulation of NKG2D and CCR5. Cancer Res. 2017, 77(7):1611-1622